StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) stock

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$4.00−0.06 (-1.48%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Taysha Gene Therapies price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Taysha Gene Therapies's price to sales ratio was 253.8× on Nov 11, 2026, against 205.8× a year earlier. Over the last 3 years it ranged from 26.4× to 337.5×, with a median of 77.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026253.8×+15.1
2025Dec 31, 2025238.8×+203.0
2024Dec 31, 202435.8×–

More Taysha Gene Therapies figures

See a number that looks wrong?